- Home
- HHS vs QTTB Comparison
HHS vs QTTB Comparison
Compare HHS & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HHS
- QTTB
- Stock Information
- Founded
- HHS 1923
- QTTB 2015
- Country
- HHS United States
- QTTB United States
- Employees
- HHS N/A
- QTTB N/A
- Industry
- HHS Advertising
- QTTB Biotechnology: Pharmaceutical Preparations
- Sector
- HHS Consumer Discretionary
- QTTB Health Care
- Exchange
- HHS Nasdaq
- QTTB Nasdaq
- Market Cap
- HHS 26.9M
- QTTB 26.3M
- IPO Year
- HHS N/A
- QTTB N/A
- Fundamental
- Price
- HHS $2.85
- QTTB $2.01
- Analyst Decision
- HHS
- QTTB Hold
- Analyst Count
- HHS 0
- QTTB 7
- Target Price
- HHS N/A
- QTTB $12.17
- AVG Volume (30 Days)
- HHS 20.7K
- QTTB 84.4K
- Earning Date
- HHS 11-10-2025
- QTTB 11-13-2025
- Dividend Yield
- HHS N/A
- QTTB N/A
- EPS Growth
- HHS N/A
- QTTB N/A
- EPS
- HHS N/A
- QTTB N/A
- Revenue
- HHS $166,841,000.00
- QTTB N/A
- Revenue This Year
- HHS $6.54
- QTTB N/A
- Revenue Next Year
- HHS N/A
- QTTB N/A
- P/E Ratio
- HHS N/A
- QTTB N/A
- Revenue Growth
- HHS N/A
- QTTB N/A
- 52 Week Low
- HHS $2.33
- QTTB $1.35
- 52 Week High
- HHS $6.20
- QTTB $28.66
- Technical
- Relative Strength Index (RSI)
- HHS 44.36
- QTTB 38.52
- Support Level
- HHS $2.73
- QTTB $1.91
- Resistance Level
- HHS $2.87
- QTTB $2.42
- Average True Range (ATR)
- HHS 0.15
- QTTB 0.22
- MACD
- HHS 0.02
- QTTB -0.06
- Stochastic Oscillator
- HHS 75.64
- QTTB 13.66
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About QTTB Q32 Bio Inc. Common Stock
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.